Advanced Enzyme Tech
Market cap ₹3,031 Cr
- P/E
- 18.57
- Day range
- ₹276.50 – ₹284.00
- 52-week range
- ₹246.80 – ₹419.00
- Volume
- 1.71 L
- Open
- ₹284.00
- Prev close
- ₹283.15
Latest results · Q2 FY27(consolidated)Revenue ₹215 Cr+16.2%Profit ₹51 Cr+14.4%Margin 23.8%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
ADVENZYMES in NSE indices and F&O
Research profile
Composite 54 / 100Factor percentiles
Derived metrics
- Earn. yield
- 5.4%
- Graham no.
- ₹222.09
- vs Graham
- -21.0%
- ROE ÷ P/B
- 6.0%
- 12-1 mom.
- -14.0%
- Return / vol
- -0.26
- Magic Formula
- #205
- Piotroski
- 4/6
- FCF yield
- 3.4%
- PEG
- 1.29
Appears in 9 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Advanced Enzyme TechADVENZYMES | ₹3,031 Cr | 18.57 | 1.91 | 11.4% | 14.0% | 34.0% | 0.03 | +16.2% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Key metrics
- P/E (TTM)
- 18.9
- Price / Book
- 1.89
- ROE (FY26)
- 11.4%
- ROCE (latest year)
- 14%
- Dividend yield
- 1.90%
Moving averages (NSE)
- 20-day
- ₹272.17
- Price above
- 50-day
- ₹278.31
- Price above
- 200-day
- ₹308.99
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- FII
- DII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 161 | 158 | 155 | 146 | 169 | 167 | 186 | 185 | 172 | 203 | 192 | 215 |
| YoY Sales growth | — | — | — | -7 | — | — | — | — | — | — | — | — |
| Expenses | 107 | 102 | 103 | 104 | 114 | 122 | 129 | 124 | 123 | 140 | 139 | 142 |
| Operating Profit | 54 | 55 | 51 | 42 | 55 | 46 | 56 | 60 | 49 | 63 | 53 | 72 |
| OPM % | 33% | 35% | 33% | 29% | 33% | 27% | 30% | 33% | 29% | 31% | 28% | 34% |
| Other Income | 14 | -6 | 7 | 10 | 8 | 9 | 9 | 10 | 20 | 7 | 11 | 9 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 11 |
| Profit before tax | 59 | 40 | 49 | 42 | 53 | 43 | 55 | 60 | 58 | 60 | 54 | 69 |
| Tax % | 28% | 25% | 28% | 21% | 27% | 38% | 26% | 25% | 26% | 24% | 28% | 26% |
| Net Profit | 42 | 30 | 35 | 33 | 39 | 27 | 40 | 45 | 43 | 45 | 39 | 51 |
| EPS in Rs | ₹3.74 | ₹2.53 | ₹3.05 | ₹2.94 | ₹3.37 | ₹2.37 | ₹3.57 | ₹3.87 | ₹3.80 | ₹3.84 | ₹3.31 | ₹4.31 |
From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+8 days since Mar 2021
-11 days since Mar 2021
+20 days since Mar 2021
-22 days since Mar 2021
+22 days since Mar 2021
Strengths, risks & growth
Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes. [1]
Strengths
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 40.9%
Risks
- The company has delivered a poor sales growth of 8.24% over past five years.
- Company has a low return on equity of 10.4% over last 3 years.
Compounded Sales Growth
- 10 Years
- +10%
- 5 Years
- +8%
- 3 Years
- +11%
- TTM
- +11%
Compounded Profit Growth
- 10 Years
- +7%
- 5 Years
- +2%
- 3 Years
- +14%
- TTM
- +10%
Stock Price CAGR
- 10 Years
- -3%
- 5 Years
- -4%
- 3 Years
- -4%
- 1 Year
- -14%
Return on Equity
- 10 Years
- +13%
- 5 Years
- +10%
- 3 Years
- +10%
- Last Year
- +11%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 43.04% | 43.26% | 43.25% | 43.56% | +0.31 pp |
| FII | 25.85% | 25.50% | 26.70% | 26.64% | -0.06 pp |
| DII | 5.51% | 5.41% | 4.77% | 1.89% | -2.88 pp |
| Public | 25.62% | 25.85% | 25.28% | 27.90% | +2.62 pp |
Filed with NSE for Sept 2026: promoters 43.56%, public 56.44%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 1.18% (-0.64 pp)- Promoters43.6%
- Foreign institutions26.6%
- Mutual funds1.2%
- Insurance0.0%
- Other domestic institutions0.7%
- Retail17.1%
- Others10.8%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| UTI MNC Fund | 0.92% | 1.12% | -0.11 pp |
| Motilal Oswal Nifty Microcap 250 Index Fund | 0.12% | 0.15% | -0.01 pp |
| JioBlackRock Flexi Cap Fund | 0.06% | 0.06% | -0.01 pp |
| Groww Nifty Total Market Index Fund | 0.00% | 0.01% | -0.00 pp |
| Bandhan BSE Healthcare Index Fund | 0.00% | 0.08% | -0.01 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 37.0%
- Downside volatility
- 36.5%
- Worst 5% of days
- 3.4%
- Average of that tail
- 5.6%
- Max drawdown (1Y)
- 36.7%
- Below its peak
- 28.3%
Against the market
- Beta vs Nifty 50
- 0.97
- Correlation
- 0.35
- Relative strength (3M)
- -11.9%
- ATR (14)
- 3.1%
Return
- Return 1M
- +5.2%
- Return 3M
- -8.0%
- Return 6M
- -22.7%
- Return 1Y
- -9.5%
- vs 200-day average
- -9.1%
Momentum
- RSI (14)
- 54.7
- MACD histogram
- 1.69
- Stochastic %K
- 77.1
- ADX (14)
- 27.0
- +DI / −DI
- 16.8 / 13.8
- Money flow index
- 69.8
Participation
- Delivery (20d avg)
- 57.0%
- vs its 60-day baseline
- -0.8 pts
- Volume vs 20-day
- -0.4σ
- Close vs day's VWAP
- +0.1%
- 52-week position
- 23 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
4 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — passed
- Free cash flow
- ₹104 Cr
- FCF yield
- 3.4%
- Cash conversion
- 0.90
- Accruals ratio
- 0.009
- Net debt
- -₹105 Cr
- Net debt / equity
- -0.06
- EV / sales
- 3.75
- PEG
- 1.29
- Capex intensity
- 7.0%
- Revenue CAGR
- 18.1%
- Profit CAGR
- 54.1%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
Abhijit Kishor Rathi Gift | Buy | 15,000 | ₹0 | 2 Apr 2026 |
Amit Kishor Rathi Immediate relative · Gift | Buy | 15,000 | ₹0 | 2 Apr 2026 |
Leela Kishor Rathi Immediate relative · Gift | Sell | 45,000 | ₹0 | 2 Apr 2026 |
Ankit Kishor Rathi Gift | Buy | 15,000 | ₹0 | 2 Apr 2026 |
Vasant Rathi Promoters · Market Purchase | Buy | 18,000 | ₹53.7 L | 13 Mar 2026 |
Vasant Rathi Promoters · Market Purchase | Buy | 65,000 | ₹1.9 Cr | 10 Mar 2026 |
Vasant Rathi Promoters · Market Purchase | Buy | 55,000 | ₹1.6 Cr | 10 Mar 2026 |
Vasant Rathi Promoters · Market Purchase | Buy | 20,000 | ₹59.1 L | 10 Mar 2026 |
Vasant Rathi Promoters · Market Purchase | Buy | 20,000 | ₹58.2 L | 9 Feb 2026 |
Vasant Rathi Promoters · Market Purchase | Buy | 37,304 | ₹1.1 Cr | 7 Feb 2026 |
Vasant Rathi Promoters · Market Purchase | Buy | 21,334 | ₹61.1 L | 6 Feb 2026 |
Vasant Rathi Promoters · Market Purchase | Buy | 11,362 | ₹32.7 L | 6 Feb 2026 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- dividend₹1.35
Dividend - Rs 1.35 Per Share
24 Jul 2026ex-date - dividend₹1.20
Dividend - Rs 1.20 Per Share
23 Jul 2025ex-date - dividend₹4.00
Interim Dividend - Rs 4 Per Share
16 May 2025ex-date - dividendNot available — not reported in this filing
Dividend - Re 1.1 Per Share
18 Jul 2024ex-date - dividend₹4.00
Interim Dividend - Rs 4 Per Share
17 May 2024ex-date - dividendNot available — not reported in this filing
Dividend - Re 1 Per Share
4 Aug 2023ex-date - dividend₹4.00
Interim Dividend - Rs 4 Per Share
19 May 2023ex-date - dividendNot available — not reported in this filing
Dividend - Re 1 Per Share
11 Aug 2022ex-date - dividend₹0.90
Dividend - Rs 0.90 Per Share
31 Aug 2021ex-date - dividend₹0.60
Annual General Meeting/Dividend - Rs 0.60 Per Share
9 Jul 2020ex-date - dividend₹0.60
Annual General Meeting/Dividend - Rs 0.60 Per Share
1 Aug 2019ex-date - dividendNot available — not reported in this filing
Annual General Meeting/Dividend Re 0.50 Per Share
6 Sept 2018ex-date - dividendNot available — not reported in this filing
Annual General Meeting/Dividend - Re 0.40 Per Share(Book Closure Dates Revised)
4 Sept 2017ex-date - splitNot available — not reported in this filing
Face Value Split From Rs 10/- Per Share To Rs 2/- Per Share
25 May 2017ex-date - otherNot available — not reported in this filing
Annual General Meeting
8 Sept 2016ex-date
Company announcements
Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on October 23, 2026
Advanced Enzyme Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2026 ,inter alia, to consider and approve the Un-Audited ....
Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on October 22, 2026
Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on October 21, 2026
Intimation of receipt of request from Promoter Group Member for reclassification from Promoter Group Category to Public Category Shareholders under Regulation 31A of the SEBI (Listing Obligations ....
Intimation of receipt of request from Promoter Group Member for reclassification from Promoter Group Category to Public Category Shareholders under Regulation 31A of the SEBI (Listing Obligations ....
Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on October 19, 2026
Daily Report pursuant to Regulation 18(i) of the Buyback Regulation regarding the Equity Shares bought back on October 16, 2026
Intimation of receipt of request from few Promoter Group Members for reclassification from Promoter Group category to Public Category Shareholders under Regulation 31A of the SEBI (Listing ....
Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on October 15, 2026
Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on October 14, 2026.
Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on October 13, 2026
Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on October 12, 2026.
Please find enclosed herewith the intimation of receipt of request from few promoter group members for reclassification from Promoter Group Category to Public Category under Regulation ....
Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on October 09, 2026
Filed with BSE (scrip 540025); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Aug 2026TranscriptSlidesRecording
- May 2026TranscriptSlides
- Mar 2026Recording
- Feb 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlides
Credit ratings
- Rating update · 30 Apr from crisil
- Rating update · 13 Feb from icra
- Rating update · 30 Jan 2025 from crisil
- Rating update · 28 Dec 2023 from crisil
- Rating update · 31 Oct 2022 from crisil
- Rating update · 18 Aug 2021 from crisil
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 31 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Advanced Enzyme Tech: common questions
Answered from the figures on this page.